Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7928171 | 0.87 | BACE1 (0.34) | BACE1BACE2CTSD | |
| SCHEMBL7917913 | 0.84 | BACE1 (0.34) | BACE1BACE2KCNH2CTSD | |
| SCHEMBL12203875 | 0.84 | BACE1 (0.34) | BACE1BACE2KCNH2CTSD | |
| SCHEMBL12203870 | 0.84 | BACE1 (0.34) | BACE1BACE2KCNH2CTSD | |
| SCHEMBL7923922 | 0.84 | BACE1 (0.34) | BACE1BACE2KCNH2CTSD | |
| SCHEMBL7929352 | 0.84 | BACE1 (0.34) | BACE1BACE2KCNH2CTSD | |
| SCHEMBL7929059 | 0.82 | CYP11B1 (0.39) | BACE1CYP11B1CYP11B2BACE2KCNH2 | |
| SCHEMBL7922850 | 0.81 | BRD4 (0.40) | KCNH2 | |
| SCHEMBL7929924 | 0.81 | MAOA (0.32) | — | |
| SCHEMBL7932538 | 0.80 | ADRA1D (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8476274-B2 | Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP (US) | 2013-02-21 | — | — | US | disclosed |
| US-8324213-B2 | Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110251207-A1 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2010042473-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045914-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRA2A | BACE1 2516/4885CYP11B1 311/4885CYP11B2 71/4885 |
| US-20110251207-A1 | BIARYL-SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRB3 | BACE1 2209/4885CYP11B1 200/4885CYP11B2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.